That, in the opinion of the House, the government should continue to address the rising financial and human costs of Alzheimer's disease and other forms of dementia in Canada by ensuring, now and in the future, that its programs and policy development related to this issue continue to recognize: (a) the right to dignity and compassion of patients stricken by such conditions; (b) the emotional and psychological toll on family members and friends of patients afflicted by such conditions; (c) the increasing costs imposed on public health systems by the treatment of such conditions; and (d) the role played by such civil organizations as t ...[+++]he Alzheimer Society of Canada and Neurological Health Charities Canada in furthering our understanding of the impacts of Alzheimer's disease and other forms of dementia.

(Return tabled) Question No. 611 Ms. Kirsty Duncan: With respect to the government’s plans for resource development, as described in the section entitled “Responsible Resource Development” in Chapter 3.2 of Budget 2012: (a) what are all examples of federal environmental laws that are stronger than provincial laws and how will the proposed legislative changes to the Canadian Environmental Assessment Act (CEAA) affect the assessment of environmental impacts of industrial projects that cross provincial borders; (b) what research, action ...[+++], or investment has the government undertaken to study impacts of the proposed legislative changes to the CEAA on (i) regulatory decision-making, (ii) risk of project-specific and cumulative environmental impacts, (iii) risk mitigation by developers, (iv) Canada’s reputation; (c) what briefing notes, memos, or any other documentation, including, for each, the details of its findings and recommendations, have been provided to the Prime Minister, Minister of Natural Resources, Minister of the Environment, their respective Parliamentary Secretaries, their respective Deputy Ministers, and their respective staff members, regarding impacts of the proposed legislative changes to the CEAA on (i) regulatory decision-making, (ii) risk of project-specific and cumulative environmental impacts, (iii) mitigation by developers, (iv) Canada’s reputation; (d) will the proposed legislative changes to the CEAA give any consideration to (i) measuring negative impacts of development, (ii) managing negative impacts of development; (e) by what date will the government bring forth new “legislation to streamline the review process for major economic projects” (Budget 2012, p. 89); (f) what are the projected costs of changes to the CEAA for each province and territory; (g) what assessments of the adequacy of the environmental assessment process in each province and territory have been conducted, (i) what were the dates of any such assessments, (ii) what wer ...

(Return tabled) Question No. 8 Ms. Judy Wasylycia-Leis: With respect to the government’s actions to detect, prevent and treat Lyme disease in Canada: (a) by what standard is the accuracy of Lyme disease testing conducted at the National Microbiological Laboratories evaluated; (b) when was the most recent independent evaluation of the proficiency of this testing conducted, by whom and what were the results; (c) what are the current criteria for determining whether a geographical area is deemed to be endemic for Lyme-infected ticks; (d) what is the projected schedule of field study with regard to ...[+++]such endemic areas; (e) with respect to the recommendations of the National Conference on Lyme Disease hosted by the Public Health Agency of Canada (PHAC) in March 2006, (i) have the committees to develop new guidelines on surveillance, clinical and laboratory criteria been formed and, if so, when have they met, (ii) what stakeholder groups have participated in the development of new guidelines, what form has that participation taken, and when did it occur; (f) what is the government's strategy to protect canadians from the increase in incidents of Lyme disease anticipated by PHAC; (g) what is PHAC's strategy to increase (i) physicians' and other health professionals' awareness of the symptoms of Lyme disease, (ii) the canadian public's awareness of the symptoms of Lyme disease; (h) what measures has the PHAC taken in conjunction with provincial health authorities to increase professional and public awareness; (i) what are PHAC's measurable targets for the future increase of awareness and diagnostic accuracy of Lyme disease; (j) does Health Canada recommend the screening of blood for Lyme disease or co-infections such as babesiosis, as done in the United States and, if not, why not; and (k) what research projects into lyme borelia and tick-borne co-infections, their epidemiology, their possible role in the occurence of other diseases, and their treatment are current ...

An independent external evaluation should be undertaken to assess the impact of the Centre on the prevention and control of human disease and the possible need to extend the scope of the Centre’s mission to other relevant Community-level activities in public health, in particular to health monitoring.

CONSIDERS IT NECESSARY that an analysis and evaluation of the safety, effectiveness and impact of vaccines to prevent distinct communicable diseases, of the risks related to communicable diseases and of the usefulness of vaccinations is periodically carried out in the European Union on the basis of developments in scientific knowledge.

(e) implementing hygiene and infection control standards in institutions (hospitals, child care facilities, nursing homes etc.) and in the community, and assessing their impact in the prevention of communicable diseases and the need for antimicrobial agents.